Stabilizing the native trimer of HIV-1 Env by destabilizing the heterodimeric interface of the gp41 postfusion six-helix bundle by Kesavardhana, Sannula & Varadarajan, Raghavan
Stabilizing the Native Trimer of HIV-1 Env by Destabilizing the
Heterodimeric Interface of the gp41 Postfusion Six-Helix Bundle
Sannula Kesavardhana,a Raghavan Varadarajana,b
Molecular Biophysics Unit, Indian Institute of Science, Bangalore, Indiaa; Jawaharlal Nehru Centre for Advanced Scientific Research, Jakkur, Bangalore, Indiab
ABSTRACT
The HIV-1 envelope glycoprotein (Env) is a trimer of gp120-gp41 heterodimers and is essential for viral entry. The gp41 subunit
in native, prefusion trimeric Env exists in a metastable conformation and attains a stable six-helix bundle (6-HB) conformation
comprised of a trimer of N-heptad repeat (NHR) and C-heptad repeat (CHR) heterodimers, that drives the fusion of viral and
cellular membranes. We attempted to stabilize native Env trimers by incorporation of mutations at the NHR-CHR interface that
disrupt the postfusion 6-HB of gp41. The mutations V570D and I573D stabilize native Env of the HIV-1 JRFL strain and occlude
nonneutralizing epitopes to a greater extent than the previously identified I559Pmutation that is at the interface of the NHR
trimers in the 6-HB. The mutations prevent soluble-CD4 (sCD4)-induced gp120 shedding and 6-HB formation. In the context of
cell surface-expressed JRFL Env, introduction of a previously reported additional disulfide between residues A501 and T605 per-
turbs the native conformation, though this effect is partially alleviated by furin coexpression. The data suggest that positions 570
and 573 are surface proximal in native Env and that the NHR homotrimeric coiled coil in native Env terminates before or close to
residue 573. Aspartic acid substitutions at these positions stabilize native trimers through destabilization of the postfusion 6-HB
conformation. These mutations can be used to stabilize Env in a DNA vaccine format.
IMPORTANCE
Themajor protein on the surface of HIV-1 is the envelope (Env) glycoprotein. Env is a trimer of gp120-gp41 heterodimers. gp120
is involved in receptor/coreceptor binding and gp41 in the fusion of viral and cellular membranes. Like many other viral fusion
proteins, the gp41 subunit in native trimeric Env exists in a metastable conformation. gp41 readily forms a stable six-helix bun-
dle (6-HB) conformation comprised of a trimer of N-heptad repeat (NHR) and C-heptad repeat (CHR) heterodimers that drives
fusion of viral and cellular membranes. While it is expected that native Env is a good immunogen, its metastability results in ex-
posure of immunodominant nonneutralizing epitopes. In the present study, we stabilize native Env trimers by incorporation of
a number of different mutations at the NHR-CHR interface that disrupt the postfusion 6-HB of gp41. The stabilized constructs
described here can be incorporated into DNA vaccine candidates.
The HIV-1 envelope glycoprotein (Env) is synthesized as agp160 precursor protein that is cleaved into surface-exposed
gp120 and membrane-anchored gp41 subunits. The gp120 and
gp41 subunits associate noncovalently to make a functional trim-
eric envelope spike on the virion surface (1, 2). Trimeric Env is
essential for host cell recognition and subsequent membrane fu-
sion. During the process of fusion, the envelope spike samples
different conformations to achieve fusion of cellular and viral
membranes. Binding of gp120 to CD4 induces structural rear-
rangements in Env and results in an active, open, quaternary con-
formation where gp120 subunits move apart and the coreceptor
binding site on gp120 is exposed (3). Binding of coreceptor
(CCR5/CXCR4) leads to the formation of a pre-hairpin interme-
diate and gp120 shedding, followed by stable gp41 six-helix bun-
dle (6-HB) formation. Native unliganded Env is known to be un-
stable on the virion surface, as themembrane-bound gp41 subunit
in the trimer exists in a metastable conformation that eventually
transforms into a stable 6-HB conformation following fusion (4).
Env protein is the primary target for vaccine design because it is
surface accessible and an essential molecule for HIV-1 entry (1).
In HIV-1 infection, viruses elicit largely Env-directed antibodies,
but with limited neutralization capacity (5). The low neutraliza-
tion potency is due in part to immunodominant epitopes in shed
gp120 and unprocessed Env on the virus surface (6, 7). Combined
with a high mutational rate and extensive glycosylation, this facil-
itates immune evasion (8, 9). The structure of monomeric gp120
has been determined in its unliganded and ligand-bound states (8,
10). It has been shown that vaccine candidates based on mono-
meric gp120 are poor immunogens that have so far failed to elicit
a protective immune response against HIV-1 (11, 12). Monomer-
ic-gp120-based immunogens elicit antibodies that typically pro-
tect against infectionwith homologous or easy-to-neutralize tier 1
viral isolates (12, 13). A recently completed RV144 clinical trial
study, where monomeric gp120 (a combination of subtypes B/E)
was used as a vaccine candidate, showed 31.2% efficacy and is
the most encouraging HIV-1 vaccine trial to date (14). Though
sera from the RV144 clinical trial did not neutralize circulating
viruses (15), the vaccine still confers partial protection.
Trimeric Env immunogens are thought to be better immuno-
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gens than monomeric gp120. Native trimeric Env expressed on
the HEK 293T cell surface bound neutralizing antibodies (NAbs)
efficiently, whereas nonneutralizing antibodies did not bind or
bound weakly (16). Previous reports suggested that the gp120
conformation in the context of the Env spike is the structure rec-
ognized by many neutralizing antibodies. Quaternary epitope-
specific neutralizing antibodies bind to gp120 in its trimeric Env
context with much higher affinity than the corresponding mono-
meric form (17, 18). Amajor obstacle inHIV-1 vaccine research is
the lack of an atomic resolution structure for the native Env
trimer. Recently, the cryo-electron microscopy (cryo-EM) and
crystal structures of trimeric disulfide-stabilized gp140 were de-
termined (19–21). While these produce valuable information on
the relative orientations of the gp41 N-heptad repeat (NHR) and
C-heptad repeat (CHR) and gp120, no side chain coordinates for
gp41 are present in these structures. Although native trimeric Env
is believed to be a better immunogen thanmonomeric gp120 (22),
the design and purification of Env glycoprotein in its native trim-
eric form is difficult and challenging due to the instability and
misfolding of the purified functional HIV-1 Env trimer.
Various approaches have been explored to design trimeric Env
immunogens in which the protease cleavage site between gp120
and gp41 was mutated so that the two subunits remained cova-
lently linked (23, 24). In an alternative approach, a disulfide bond
was introduced between gp120 and gp41 (25–28). The trimeric
immunogen candidates designed so far have failed to elicit anti-
bodies that can neutralize diverseHIV-1 isolates, although there is
some improvement in eliciting neutralizing antibodies relative to
monomeric gp120 (29). Thus, the design and purification of na-
tive-like Env trimers is an important problem in HIV-1 vaccine
development. Lack of a high-resolution native trimeric Env crystal
structure, weak noncovalent interaction between gp120 and gp41
subunits, and ametastable conformation of Env hinder the design
of native-like trimeric Env immunogens.
In the present study, we designed and characterized mutations
that destabilize the stable postfusion conformation of gp41 and
examined the stability of Env in the presence of such 6-helix bun-
dle-destabilizing (6-HBD) mutations. Mammalian cell surface
display of HIV-1 Env trimers was used to probe the conforma-
tional changes of the native Env trimer in the presence of 6-HBD
mutations. Mutating residues present at the interface of the N-
heptad and C-heptad repeat regions of the 6-HB conformation of
gp41 prevented postfusion six-helix bundle formation and re-
tained the conformational integrity of the native Env trimer.
These 6-HBD mutations prevent soluble-CD4 (sCD4)-induced
gp120 shedding, presumably by stabilizing the native conforma-
tion of Env. We anticipate that this information can be used to
design improved trimeric immunogens and can also be incorpo-
rated into DNA vaccine constructs.
MATERIALS AND METHODS
Constructs. REJO, DU156, ZM109, SF162, and DU422 Env clones were
obtained from the NIH AIDS Reagent and Reference Program, Division
of AIDS, NIAID, NIH. The REJO, DU156, SF162, and DU422 Env genes
were expressed from the pcDNA3.1 plasmid, and theZM109Env genewas
expressed from the pCR3.1 plasmid. The pSVIII-JRFL gp160dCT plasmid
encodes envelope glycoproteinwith a cytoplasmic tail truncated at residue
711. The HIV-1 strain JRFL gp160dCT gene in this plasmid is the non-
codon-optimized viral sequence. The pctat expression plasmid encodes
the HIV-1 tat protein. I559P, V570D, I573D, and S649D mutations were
introduced individually into the JRFL gp160dCT background to make
gp160-I559P, gp160-V570D, gp160-I573D, and gp160-S649D by site-di-
rected mutagenesis. Also, I559P and V570D mutations were introduced
into pCDNA3.1-DU422 Env by site-directed mutagenesis. A501C and
T605C mutations were introduced into pSVIII-JRFLgp160dCT by site-
directedmutagenesis tomake gp160-SOS. In the gp160-SOS background,
I559P or V570D mutations were introduced to make gp160-SOSIP or
gp160-SOS-V570D constructs. The E168Kmutation was introduced into
gp160dCT and gp160-V570D to make gp160-E168K and gp160-V570D-
E168K constructs for PG9 and PG16 binding studies. The E168K muta-
tion was previously shown to confer PG9/PG16 binding on JRFL Env.
This mutation was also introduced into gp160-SOSIP and gp160-SOS-
V570D. Tomake JRFL gp160 cleavage defective, the gp120-gp41 cleavage
site region REKR was mutated to SEKS by site-directed mutagenesis. In
another construct, to enhance the cleavage efficiency of gp160, we re-
placed the cleavage site (REKR) with six arginine residues (R6) to make
gp160dCT-R6-E168K. Previous studies showed that replacement of the
REKR cleavage site with R6 improved the cleavage of gp160 to gp120 and
gp41 (30). Unless otherwise stated, all mutations were made in the back-
ground of the JRFL Env sequence. Residue numbering follows the con-
ventional HXBc2 numbering scheme.
Transient transfection of Env plasmids. One day prior to transfec-
tion, 3 106 293T cells were seeded in a T75 culture flask. After 24 h, the
cells were transfected with pSVIII JRFL gp160dCT expression plasmids
encoding wild-type (wt) Env and 6-HBD mutants. In all cases, the tat
expression plasmid (pctat) was cotransfected using Polyfect (Qiagen)
transfection reagent unless otherwise stated. The cells were harvested 48 h
after transfection for analysis.
Staining of cell surface-expressed Env for FACS analysis. After 48 h
of transfection, the cells were harvested with phosphate-buffered saline
(PBS) (pH 7.4) containing 5 mM EDTA and washed with fluorescence-
activated cell sorter (FACS) buffer (PBS, 5% fetal bovine serum, and
0.02% azide). The harvested cells (4  105 cells per tube) were stained
with the desired antibody for 1 h at 4°C. The antibody-cell mixture was
washed in FACS buffer, and anti-human IgG phycoerythrin (PE) (Sigma)
at 1:100 dilution was added and incubated for 1 h at 4°C. The cells were
washed again with FACS buffer before analysis. Anti-rabbit IgG-PE
(Sigma) at 1:100 dilution was used for labeling when cells were stained
with anti-gp120 rabbit polyclonal sera and anti-mouse IgG-PE for D49
antibody-stained cells. The stained cells were analyzed on a FACS analyzer
(BD FACSCantoII or BD Accuri).
After harvesting, cell viability was determined by the trypan blue dye
exclusionmethod. A cell viability test was done prior to each FACS exper-
iment for accurate determination of cell membrane integrity, and the
result was typically 80%. The cells were gated on forward scatter and
side scatter (FSC-SSC) plots to discriminate between dead cells, doublets,
and live or single cells. Themean fluorescence intensity (MFI) values were
obtained from the gated single-cell population. In each experiment, un-
stained controls, secondary-antibody controls, and untransfected cells
with primary- and secondary-antibody controls (Fig. S4) were prepared
in parallel with test samples. Each FACS experiment was repeated inde-
pendently (with independent transfection experiments) to check for con-
sistency of results. BD FACS-Diva, BD Accuri, and FlowJo software was
used to analyze the data and to obtain statistical information.
sCD4-induced gp120 shedding experiments. (i) ELISA.After 48 h of
transfection, cells were harvested and washed with FACS buffer. The har-
vested cells (1  106 cells per tube) were incubated in the presence and
absence of sCD4 (four-domain sCD4, obtained from the Neutralizing
Antibody Consortium [NAC]) at various concentrations for 2 h at 4°C
with occasional mixing of samples. The cells were centrifuged at 210 g
for 2 min, and the supernatant containing shed gp120 was collected. Each
well of a 96-well enzyme-linked immunosorbent assay (ELISA) plate
(Nunc) was coated with 200 ng of gp120-capturing antibody (D7324)
overnight at 4°C. Supernatants containing shed gp120were added to these
D7324-coated plates and incubated for 1 h at room temperature. After 1 h,
the wells were washed four times with PBS, 0.025%Tween 20 (PBST) four
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times. To detect captured gp120, 2G12 antibodywas added and incubated
for 1 h at room temperature. Samples werewashed again, and anti-human
IgG antibody conjugated to alkaline phosphatase (Sigma) was added and
incubated at room temperature for 1 h. After a wash, developing solution
(p-nitrophenyl phosphate; Sigma) was added, and the absorbance was
measured at 410 nm using a Spectramax Plus 384 (Molecular Devices,
USA).
(ii) FACS. After 48 h of transfection, cells were harvested and washed
with FACS buffer. The harvested cells (1 106 cells per tube) were incu-
bated with or without sCD4 at 50-g/ml concentration for 2 h at 4°Cwith
occasional mixing. To remove shed gp120, the cells were washed with
FACS buffer. Then, the cells were incubated with either 2G12 antibody or
D49 antibody at various concentrations for 1 h at 4°C. After a wash, the
cells were incubated with anti-human IgG-PE (Sigma) to stain 2G12 an-
tibody-bound cells and with anti-mouse IgG-PE (Sigma) to stain D49
antibody-bound cells. After a wash, the cells were analyzed on a FACS
analyzer (BD Canto or BD Accuri). BD FACS-Diva 6.1.3 and BD Accuri
software was used to analyze the data.
SPR experiments. Surface plasmon resonance (SPR) experiments
were performed with a Biacore 2000 (Biacore, Uppsala, Sweden) optical
biosensor at 25°C. Briefly, 800 resonance units (RU) of b12 and b6
antibodies were immobilized by amine coupling to the surface of a CM5
chip. The binding of DU422 gp120 to these antibodies was examined.
DU422 gp120 was passed across each sensor surface at different concen-
trations.
Western blot analysis. The cells were harvested after 48 h of transfec-
tion, and the harvested cells (3 106) were subjected to cell lysis in 200l
cell lysis buffer (10 mMTris, 0.15 MNaCl, 1%NP-40 detergent, protease
inhibitor cocktail, pH 8) for 1 h on ice. The lysed cells were centrifuged at
15,000 g for 30min. The cell lysates were separated from cell debris and
stored at80°C till further use. Forty microliters of cell lysate from each
transfectionwas subjected to SDS gel electrophoresis and then transferred
to a nitrocellulose membrane to probe with rabbit anti-gp120 polyclonal
serum (1:1,000 dilution). The blots were labeled with anti-rabbit IgG-
peroxidase (Sigma) at 1:5,000 dilution and developed with enhanced
chemiluminescence (ECL) substrate to detect Env proteins.
RESULTS
Expression of trimeric Envs from various different HIV-1 sub-
types.Using a yeast surface two-hybrid (YS2H) system, we previ-
ously succeeded in reconstituting the postfusion six-helix bundle
of HIV-1 gp41 on the yeast surface by expressing the NHR from
gp41 as a membrane-anchored prey and the CHR as a secretory
bait (31). This system allowed us to rapidly characterizemutations
destabilizing 6-HB formation. The 6-HB consists of a central
NHR trimer with a CHR peptide bound to each NHR (4). Muta-
tions to disrupt helix-helix interactions in the 6-HB involved ei-
ther mutations disrupting NHR trimer formation or those in-
volved in interactions between the NHR and the CHR. Among
various mutations screened previously (31) the I559P, V570D,
I573D, and S649Dmutations destabilized six-helix bundle forma-
tion on the yeast surface (Fig. 1). In the present study, we exam-
ined the effects of 6-HBD mutations on Env trimer stability and
integrity.
Earlier studies have shown that when JRFL gp160 truncated at
its cytoplasmic tail (JRFL gp160dCT) is expressed on the HEK
293T cell surface, gp160 is efficiently processed into gp120 and
gp41, and native-like Env oligomers are displayed on the cell sur-
face (16, 32, 33). These cleaved, surface-expressed Env oligomers
were probed for binding to neutralizing and nonneutralizing
antibodies by FACS. Properly cleaved native Env trimers bind
FIG 1 Six-helix bundle-destabilizing mutations. (a) Helical-wheel diagram of postfusion 6-HB. Residues essential for NHR trimer formation (purple) and
residues essential for CHR interaction with NHR to form 6-HB (cyan) are highlighted. (b) Postfusion six-helix bundle of gp41 (Protein Data Bank [PDB] ID,
3CP1) generated using PYMOL (PYMOL molecular graphics system version 1.2r2; DeLano Scientific, LLC). Residues mutated for 6-HB disruption are
represented in space-fillingmode. TheNHR region is shown in orange and the CHR region in green. (c) Sequences of NHR andCHR regions from the JRFL gp41
subunit. Residues individually mutated to disrupt 6-HB formation are highlighted. The NHR region is highlighted in orange, and the CHR region is highlighted
in green.
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selectively to CD4 binding site (CD4bs)-directed neutralizing
antibodies, such as b12, but not to corresponding nonneutral-
izing antibodies, such as b6 and F105, as well as other nonneu-
tralizing antibodies specific to different regions of Env (16).
However, uncleaved Env (JRFL gp160-SEKS) on the cell sur-
face bound equally well to both b12 and b6 and also showed
significant binding to other nonneutralizing antibodies. In ad-
dition to this, previous reports showed that HIV-1 JRFL Env
glycoprotein expressed on the cell surface by transient trans-
fection is oligomeric and predominantly trimeric (34). Hence,
we used FACS combined with cell surface expression to char-
acterize mutations that selectively destabilize the postfusion
six-helix bundle, but not native trimeric Env.
We initially characterized cell surface expression of Env from
various subtypes to select an HIV-1 Env that is well displayed on
the cell surface. Various Env glycoproteins from clade B (SF162,
REJO, and JRFL) and clade C (DU156, ZM109, and DU422)
HIV-1 strains were expressed on the HEK 293T cell surface indi-
vidually. SF162, REJO, DU156, ZM109, and DU422 Env clones
are full-length Env plasmids. In the JRFL Env clone, the Env gene
was truncated at the cytoplasmic tail (35). The JRFL Env expres-
sion level was higher than those of other strains, possibly because
of this truncation. Apart from expression levels, cell surface ex-
pression allowed us to compare Env integrity. To examine native
Env integrity, Env-expressing cells were stained with CD4bs-di-
rected neutralizing and nonneutralizing antibodies. Properly
cleaved trimeric Env efficiently binds neutralizing antibodies but
not nonneutralizing antibodies. Forty-eight hours after transfec-
tion, cells were harvested and stainedwith CD4bs site neutralizing
(b12) and nonneutralizing (b6) antibodies to screen for an Env
that was cleavage competent and native-like based on the previ-
ously established FACSmethod (16). Clade B isolates boundmore
efficiently to neutralizing (b12) than to nonneutralizing (b6) an-
tibodies (see Fig. S1a in the supplemental material). JRFL Env
showed the largest difference between neutralizing- and nonneu-
tralizing-antibody binding (6-fold), which indicates good dis-
play of cleavage-competent trimeric Env on the cell surface (see
Fig. S1b in the supplemental material). In the case of clade C
isolates, DU422 Env showed ameasurable difference between b12
and b6 antibody binding. JRCSF and YU2 subtype Envs also ex-
hibited less discrimination than JRFL in b12 and b6 antibody
binding patterns (16, 17). Recent studies also suggest that Env
glycoprotein fromHIV-1 JRFL is homogeneous and trimeric (36).
Thus, in further experiments, we chose JRFL-Env glycoprotein for
characterizing 6-HBD mutations in the context of native Env
trimers and confirmed the generality of the observations by study-
ing the effects of identical mutations in DU422 Env.
Antigenicityprofiles suggest thatmost 6-HBDmutationsdid
not perturb the native conformation. The previously character-
ized six-helix bundle-destabilizing mutations (I559P, V570D,
I573D, and S649D) disrupt six-helix bundle formation in a yeast
surface two-hybrid system (31). Thesemutationswere introduced
individually into non-codon-optimized JRFL gp160 (truncated at
its cytoplasmic tail) in order to stabilize trimeric Env in a native-
like conformation by disrupting six-helix bundle formation. De-
stabilizing six-helix bundle formation in gp41 might be expected
to stabilize gp41 in its native conformation, since formation of the
6-HB is an irreversible step that prevents reformation of the native
gp120-gp41 trimer. We have previously used a similar strategy to
stabilize the stem domain of hemagglutinin in influenza virus in
its native conformation (37, 38). The previously described muta-
tions to make Env cleavage defective (REKR to SEKS) were also
introduced into non-codon-optimized JRFL gp160 (16, 39). To
study the effects of mutations on trimer integrity, HEK 293T cells
were cotransfected with each of the gp160 mutants, along with a
tat expression plasmid. The cells were harvested after 48 h and
processed for FACS analysis to examine binding to various gp120-
and gp41-directed antibodies. The overall level of Env surface ex-
pressionwas probedwithmannose-specific 2G12monoclonal an-
tibody. The MFIs from FACS histograms were plotted as a func-
tion of the antibody concentration to generate binding curves.
The cells transfected with wt gp160 and six-helix bundle-de-
stabilizing mutants (gp160-V570D and gp160-I573D) bound
neutralizing antibody b12 more efficiently than the nonneutraliz-
ing antibody b6 (5- to 6-fold difference) (Fig. 2a and b). How-
ever, the gp160-I559Pmutant showed less binding to b12 than wt
gp160 and gp160-V570D, and the discrimination between b12
and b6 binding was significantly less for I559P than for wt gp160,
gp160-V570D, gp160-I573D, and gp160-S649D (P 0.05, using a
two-tailed unpaired t test at an antibody concentration of 10 g/
ml) (Fig. 2b). gp160-S649D also behaved similarly to wt gp160 in
relative b12 and b6 antibody binding patterns, though the binding
MFIs were lower (Fig. 2a). Cleavage-defective Env (JRFL gp160-
SEKS) bound equally well to b12 and b6, as reported previously
(16) (Fig. 2). In all Env 6-HBD mutants, the b12 epitope confor-
mation is retained. These data suggest that V570D, I573D, and
S649D mutations in Env did not perturb the CD4bs epitope,
whereas I559P may have altered the native structure or cleavage
efficiency of JRFL Env. The cell surface expression levels of all
constructs were probed with 2G12 antibody and were found to be
approximately comparable, though wt gp160 showed slightly bet-
ter expression than the mutants (see Fig. S3 in the supplemental
material). Binding studies with other gp120-specific nonneutral-
izing antibodies (C11 and 17b) were also carried out. Both anti-
bodies bound significantly better to cleavage-defective Env than to
wild-type and 6-HBDmutant Env (see Fig. S2 in the supplemental
material). 17b binds to Env following CD4 binding. Hence, its
epitope is referred to as a CD4-induced (CD4i) epitope. When
incubated with soluble CD4 for a short time, all 6-HBD mutants
bound to 17b (data not shown). To extend these observations to a
subtype CHIV-1 isolate, I559P and V570Dmutations were intro-
duced into DU422 Env. When probed with different NAbs and
nonneutralizing antibodies, results similar to those for JRFL were
observed (Fig. 3).
To demonstrate the effect of Env cleavage on the FACS binding
pattern of neutralizing (b12) andnonneutralizing (b6) antibodies,
we performed Western blot analysis of Env glycoproteins ex-
pressed on HEK 293T cells. Cell lysates from cleavage-defective
Env (gp160-SEKS)-expressing cells showedunprocessed gp160, as
expected (see Fig. S2 in the supplemental material). As previously
reported, there are two different gp160 species in cleavage-defec-
tive Env cell lysates (16). The higher-molecular-weight species is
the hyperglycosylated gp160, which is a predominant form of un-
cleaved Env (16). In cell lysates from wt gp160 (gp160-REKR)-
expressing cells,most of the fraction is gp120, which is the product
of gp160 cleavage, though residual uncleaved gp160 was observed
(see Fig. S2 in the supplemental material). This indicates that wt
gp160 is efficiently cleaved and is displayed on the cell surface.
Thus, inefficient cleavage of gp160-SEKS allowed binding of both
b12 and b6 antibodies equally well, while efficient cleavage of wt
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gp160 allowed high binding of b12, but not b6. The cell lysates
from gp160-I559P-expressing cells showed approximately equal
fractions of unprocessed gp160 and gp120, suggesting that incom-
plete cleavage of gp160-I559P contributes to the lower b12/b6
ratio observed for the mutant (Fig. 2). In contrast, gp160-V570D
cell lysates showed efficient cleavage of gp160, similar to wt gp160.
In addition to gp120-specific antibodies, gp41-specific anti-
bodies were also used to probe the integrity of Env in the presence
of 6-HBDmutations. At lower concentrations of the gp41-specific
antibodies 2F5 and 4E10, binding was low, as previously reported
(see Fig. S3 in the supplemental material). The 2G12 and b12
neutralizing antibodies bound even at 0.01g/ml, but the 2F5 and
4E10 neutralizing antibody binding signals were prominent only
at 1 g/ml. This is expected, as the 2F5 and 4E10 epitopes are
partially exposed and also neutralizeHIV-1 only at higher concen-
trations (32). All 6-HBDmutants show similar binding to 2F5 and
4E10 antibodies. The 6-HBD mutants were also probed with the
gp41-specific nonneutralizing antibody D49. This antibody
bound weakly to wild-type and 6-HBD mutant Envs but showed
significant binding to cleavage-defective Env (see Fig. S2 in the
supplemental material). This indicates that the introduction of
6-HBD mutations retained the conformation of 2F5, 4E10, and
D49 epitopes, similar to wild-type native Env. Cleavage-defective
Env (gp160-SEKS) showed significantly higher binding to 2F5
than cleavage-competent Env (wt gp160), which is consistent with
previous reports (32) (see Fig. S3 in the supplemental material).
To further probe the antigenic nature of gp120 trimers in Env
and to monitor the accessibility of nonneutralizing epitopes on
Env in the presence of 6-HBD mutations, cells were probed with
anti-gp120 polyclonal sera. Since the anti-gp120 polyclonal sera
were raised by immunization withmonomeric JRCSF gp120, they
are composed largely of nonneutralizing antibodies. Env-express-
ing cells were probed with various dilutions of anti-gp120 poly-
clonal sera. Cleavage-defective Env (gp160-SEKS)-expressing
cells bound the polyclonal sera with higher affinity than cleavage-
competent Env (wt gp160) and other 6-HBDmutants of Env (see
Fig. S3 in the supplemental material). Surprisingly, the gp160-
I559P mutant also showed slightly higher binding to polyclonal
sera, whereas gp160-V570D-, gp160-I573D-, and gp160-S49D-
expressing cells showed binding to polyclonal sera similar to that
of wt-gp160-expressing cells (see Fig. S3 in the supplemental ma-
terial). Within the limited resolution of the above-described ex-
periments, the V570D, I573D, and S649Dmutations thus did not
affect the native conformation of Env and showed negligible ex-
posure of nonneutralizing epitopes.
Our data suggest that 6-HBD mutations did not substantially
perturb the native conformation of gp41 trimers, which in turn
led to retention of a native-like gp120 trimer conformation in Env.
Though it destabilized six-helix bundle formation efficiently,
I559P appeared to perturb the native Env conformation on the cell
surface. Of the various 6-HBD mutations examined, the V570D
and I573D mutations caused the least perturbation of the native
Env trimers on the cell surface and did not bind to various Env-
directed nonneutralizing antibodies.
6-HBDmutations diminish shedding of gp120 from Env. In
the virus entry process, six-helix bundle formation occurs after
CD4-induced conformational changes (Fig. 4a) (1, 4, 40). In the
fusion process, gp120 is believed to be shed from the Env surface
once Env attains the pre-hairpin intermediate conformation (Fig.
4a). It has been previously suggested that destabilization of struc-
tures involved in fusion may stabilize Env in a native-like confor-
mation (25, 39, 41). Such mutations could either abolish the for-
mation of both the pre-hairpin intermediate and the 6-HB
(mutations that disrupt the NHR trimer) or the 6-HB alone (mu-
tations that disrupt NHR and CHR interactions). One way to
probe Env stabilization is by quantitating sCD4-induced gp120
shedding. We therefore examined whether the 6-HBDmutations
characterized above stabilize native Env by quantitating sCD4-
induced shed gp120 levels from Env expressed on the cell surface.
FIG 2 (a) Binding of gp120-directed CD4bs neutralizing (b12) and nonneu-
tralizing (b6) antibodies to cleavage-competent JRFL Env, uncleaved JRFL
Env, and JRFL Env with 6-HBD mutations. Proteins were expressed on the
surfaces of HEK 293T cells. Antibody binding was characterized by FACS.
MFIs were plotted against antibody concentrations. The experiment was re-
peated three times with similar results. wt gp160 and the gp160-V570D mu-
tants showed the best discrimination between b12 and b6. gp160-SEKS is a
cleavage site-defective mutant that shows no discrimination, in agreement
with earlier results (16, 32). The symbols represent the mean values, and the
error bars represent standard deviations derived from two independent exper-
iments. Cell surface expression was carried out in HEK 293T cells. (b) b12 and
b6 antibody binding MFI ratios were plotted as a function of the antibody
concentration to analyze the conformational integrity of the CD4bs. The
gp160-V570D, gp160-I573D, and gp160-S649D mutants showed patterns
similar to that of wt gp160, whereas gp160-I559P and gp160-SEKS showed a
significantly lower b12/b6 ratio. (P  0.05; two-tailed unpaired t test at an
antibody concentration of 10 g/ml).
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To detect shed gp120 levels, we used FACS and ELISA meth-
odologies. For ELISA,HEK 293T cells were transfected with either
wt gp160 or gp160 with 6-HBD mutations. Forty-eight hours
posttransfection, cells were harvested and incubated with sCD4
for 2 h. It has been reported that sCD4 induces conformational
changes in gp120, which leads to shedding of gp120, followed by
six-helix bundle formation (8, 42). Shed gp120 levels in superna-
tants were measured by ELISA. Shed gp120 in supernatants was
FIG 3 (a) Binding of neutralizing (b12) and nonneutralizing (b6, C11, 17b, and D49) antibodies to Env from a subtype C isolate (DU422) with I559P and V570D
mutations.DU422Env constructswere expressed on theHEK293T cell surface and probedwith different antibodies. Binding of antibodieswas characterized by FACS.
BindingMFIsare shownasa functionof theantibodyconcentration.The symbols represent themeanvalues, and theerrorbars represent the standarddeviationsderived
from two independent experiments. (b) MFI ratios of b12 and b6 antibody binding were plotted as a function of the antibody concentration to compare the CD4bs
integrity of 6-HBD mutants of DU422 Env. (c) SPR studies to confirm that monomeric DU422 gp120 retains the epitopes for b12 and b6 antibodies. Shown are
sensogramoverlays for binding of different concentrations ofmonomericDU422 gp120 to surface-immobilized b12 (left) and b6 (right) antibodies. The response units
are plotted as a function of time. TheKD (equilibrium dissociation constant) values for b12 and b6 are 240 20 nM and 340 17 nM, respectively.
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captured by a gp120 capture antibody (D7324), with which ELISA
plate wells were coated, and detected by probing with 2G12 anti-
body. wt gp160-transfected cells shed gp120 upon sCD4 incuba-
tion. Introduction of 6-HBD mutations (particularly I559P,
V570D, and I573D) greatly diminished gp120 shedding from Env
(Fig. 4b). I559P and V570Dmutants showed complete absence of
gp120 shedding from the cell surface. The gp160-S649Dmutation
did not decrease shedding, possibly because it either failed to suf-
ficiently destabilize the six-helix bundle or because it altered the
gp41 native conformation, which in turn disrupts gp120-gp41 in-
teraction (Fig. 4b).
In the FACS-based method, 48 h after transfection, cells were
harvested and incubated with sCD4 (50 g/ml) for 2 h. After
washing the cells to remove shed gp120, the cells were probedwith
2G12 antibody to probe the amount of gp120 retained on the cell
surface. The results from FACS correlated well with those from
ELISA (Fig. 4c). Only wt JRFL gp160- and JRFL gp160-S649D-
transfected cells shed gp120 upon sCD4 incubation.Other 6-HBD
mutants greatly abolished shedding of gp120when incubatedwith
sCD4 and also showed a slight increase in binding to 2G12 neu-
tralizing antibody in the presence of sCD4 (Fig. 4c).
We have also assessed the binding of cell surface-expressed
6-HBD Env mutants to D49 monoclonal antibody, an antibody
specific for the cluster I (immunodominant) region in gp41,
which is inaccessible on the native Env trimer (43, 44). The cluster
I region is occluded on Env due to gp41 and gp120 interaction.
When gp120 is shed from the cell surface, the cluster I region from
gp41 becomes accessible. The binding of D49 antibody is directly
proportional to the shedding of gp120. Forty-eight hours after
transfection, cells were harvested and incubatedwith sCD4 for 2 h.
After washing the cells to remove shed gp120, the cells were
probed with D49 antibody. As expected, D49 antibody binding to
wt gp160-expressing cells increased significantly (4-fold) after
sCD4 incubation (Fig. 5). Cleavage-defective Env (gp160-SKES)
and the S649D mutant also showed increased binding to D49 in
the presence of sCD4. I559P, V570D, and I573D mutants did not
show any change in D49 binding with and without sCD4. Cleav-
age-defective Env (gp160-SEKS) did not allow gp120 shedding
because of covalent linkage between gp120 and gp41 (Fig. 4b and
c). It bound surprisingly well to D49 antibody in the presence of
sCD4 (Fig. 5). This indicates that the cluster I region shows in-
creased accessibility upon CD4 binding in cleavage-defective Env,
FIG 4 (a) Cartoon representation of fusion based on the current understanding of the HIV-1 Env trimer-mediated fusion process. (b) 6-HBDmutants abolish
sCD4-induced shedding of gp120 fromEnv expressed on the cell surface, as determined by ELISA. Env-expressing cells were incubatedwith sCD4 to allow gp120
shedding fromEnv on the cell surface. The shed gp120 in the supernatant was collected and captured on ELISA plate wells by gp120-capturing antibody (D7324).
The amount of shed gp120 was quantitated by 2G12 antibody binding. OD, optical density. The error bars indicate the standard deviations obtained from three
independent experiments. (c) 6-HBDmutants abolish sCD4-induced shedding of gp120, as determined by FACS. 6-HBDmutant proteins were expressed on the
cell surface. Cells were incubatedwith sCD4 to induce gp120 shedding. The shed gp120 from the cell surface was washed off, and the gp120 on the cell surface was
quantitated by staining the cells with 2G12 antibody. The ratio of MFIs from sCD4-treated and untreated cells was plotted as a function of the 2G12 antibody
concentration. The error bars indicate standard deviations obtained from two independent experiments.
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even though gp41 and gp120 are covalently linked. sCD4-induced
gp120 shedding experiments suggested that 6-HBD mutations
prevented shedding of gp120 by stabilizing a native-like Env con-
formation. I559P and I573D are located at the “a” positions of the
NHR. These mutations destabilize the core NHR trimer essential
for pre-hairpin intermediate formation and 6-HB formation and
abolish gp120 shedding. In contrast, the V570D mutation is lo-
cated at the “e” position in the NHR region; it is expected to
destabilize 6-HB formation by preventing NHR and CHR inter-
actions and should show little effect on the pre-hairpin interme-
diate. Surprisingly, shed gp120 experiments showed that the
V570D mutation, apart from destabilizing 6-HB formation, also
abolished gp120 shedding.
Disulfide bond-stabilized cell surface JRFLEnv trimers devi-
ate from the native Env trimer conformation. Previous studies
have attempted to stabilize interactions between gp120 and gp41
in the Env trimer by engineering disulfide bonds between residue
501 of gp120 and 605 of JRFL gp41 (27, 39) ectodomains. This
disulfide-bonded mutant is referred to as SOS-gp140. SOS-gp140
was reported to be cleaved efficiently when expressed and was
predominantly monomeric. Further, the I559P mutation was in-
troduced into SOS-gp140 to give SOSIP-gp140. SOSIP-gp140 was
predominantly trimeric and cleaved.When immunization studies
were done with trimeric SOSIP-gp140, it elicited a marginally im-
proved antibody response compared to monomeric gp120-im-
munized animals (30, 45). The sera neutralized tier 1 viruses with
high titers and some tier 2 viruses with low titers. The cryo-EM
structure of SOSIP-gp140 was solved and compared with that of
native Env trimers (19, 40, 46). The cryo-EM and crystal struc-
tures suggest that SOSIP-gp140 showed topology similar to that of
native Env trimers (46). Hence, wemade SOS and SOSIPmutants
in a JRFL gp160 background, expressed them on the cell surface,
and probed their conformations with various antibodies.
Introduction of the SOS mutation in JRFLgp160 led to lower
levels of expression of Env on the cell surface, as probed by 2G12
binding. Thismight be due to reduced incorporation of Env in the
membrane due to mutations or formation of nonnative confor-
mations. Binding MFI values were normalized for expression lev-
els based on 2G12 antibody binding.Weobserved that the b12 and
b6 binding difference was small in SOSIP-gp160 compared to wt
gp160 trimers on the cell surface (Fig. 6a). This could be because
the engineered disulfide perturbed the native Env conformation
or could be due to inefficient cleavage of envelope after its synthe-
sis. We also tested the V570D mutation, which is a promising
6-HBD mutation, in the context of SOS-gp160 (SOS gp160-
V570D). SOS-gp160-V570D exhibited a pattern of binding to
CD4bs neutralizing andnonneutralizing antibodies similar to that
of SOSIP-gp160 (Fig. 6a). To further investigate this, we trans-
fected a plasmid encoding furin along with the disulfide con-
structs to allow improved cleavage of envelopemutants, but it did
not help (Fig. 6a). To further improve cleavage, we introduced six
arginine residues (R6) in place of the REKR cleavage sequence (a
technique that was used previously to enhance the cleavage of
SOS-gp140 [30]), which resulted in increased expression (Fig. 6a).
SOS-gp160 showed 2.5-fold difference in b12 and b6 binding,
which is better than the SOSIP-gp160 binding pattern (Fig. 6b).
Hence, the disulfide bond engineered to lock gp120 and gp41
appears to have perturbed the native conformation of Env, though
the soluble-disulfide-stabilized gp140 constructs were previously
shown to be trimeric and cleaved efficiently (26, 29). As cleavage
levels of Env correlate with the antibody binding profiles, it is
important to know the degree of cleavage of disulfide-stabilized
Env mutants. The cleavage of disulfide-stabilized Env trimers was
probed usingWestern blotting. Equal amounts of total cell lysates
of Env-expressing cells were subjected to SDS gel electrophoresis,
transferred to a nitrocellulose membrane, and probed with rabbit
anti-gp120 polyclonal sera (Fig. 6c). The cell lysates from wt-
gp160-transfected cells showed the presence of efficiently cleaved
Env (presence of gp120), though a small amount of residual un-
processed and hyperglycosylated gp160 was detected, as seen
previously (16) (Fig. 6c). Similar to wt gp160, the disulfide bond-
engineered Envs (gp160-SOSIP, gp160-SOS-V570D, and gp160-
SOS) showed efficient cleavage of gp160 with a small amount of
unprocessed gp160, though the level of expression was lower than
that of wt gp160 in all cases (Fig. 6c). Furin overexpression further
increased the cleavage of disulfide mutant Env mutants (Fig. 6c).
Cleavage-defective Env cell lysates were used as a control to indi-
cate the positions of unprocessed gp160. These results confirm
that the disulfide mutant Envs are properly cleaved and that the
lower b12/b6 binding ratios relative to the wild type in the SOS
mutants are due to altered Env conformation rather than de-
creased cleavage.
FIG 5 6-HBD mutations prevent sCD4-induced shedding of gp120 and di-
minish the accessibility of the gp41 cluster I epitope while retaining gp120-
gp41 interactions. The gp41 cluster I region is an immunodominant region
that is occluded due to gp120-gp41 interactions in native trimers. Shedding of
gp120 results in an increase in the accessibility of the cluster I region recog-
nized by the monoclonal antibody D49. To examine the ability of 6-HBD
mutations to abolish gp120 shedding and to retain gp120-gp41 interactions,
Env-expressing cells were stained with D49 antibody after sCD4-induced
gp120 shedding from the cell surface.MFIs are plotted as a function of theD49
antibody concentration. The error bars indicate the standard deviations ob-
tained from two independent experiments.
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We have also examined the binding of gp41 MPER antibodies
to SOS-gp160 mutants. The 2F5 and 4E10 epitopes are partially
accessible to these antibodies in native Env and are exposed during
the fusion process, particularly in the pre-hairpin intermediate
stage (4, 47–49). Consequently, the 2F5 and 4E10 antibodies neu-
tralize HIV-1 only at high concentrations, and a recent study has
shown that these antibodies required prolonged incubation times
to completely inactivate the virus (50). We examined the binding
of 2F5 and 4E10 antibodies to SOS-gp160 mutants. Both gp160-
SOSIP and SOSgp160-V570D bound better to 2F5 (4-fold) and
4E10 (3-fold) antibodies than wt gp160 (Fig. 7). Transfection of
disulfide Envmutants with furin or replacement of REKR with an
R6 cleavage site did not result in any significant change (Fig. 7).
The high binding of 2F5 and 4E10 antibodies to disulfidemutants
suggests increased accessibility of the MPER region in gp41, con-
sistentwith a perturbed trimer conformation. TheMPER region is
occluded in the native trimeric Env complex. A recent study
showed that the 2F5 epitope is accessible on laboratory-adapted
sensitive viruses, but not on neutralization-resistant viruses, such
as JRFL (49). Thus, these results indicate that disulfide engineer-
FIG 6 Engineered disulfide bonds between gp120 and gp41 perturb the native conformation of JRFL Env. Disulfide bond (SOS) mutants of Env were expressed
on theHEK 293T cell surface. (a) Disulfide bond Envmutants with I559P andV570Dmutations. To probe for conformational similarity to native Env, cells were
stained with CD4bs neutralizing (b12) and nonneutralizing (b6) antibodies. Antibody binding was characterized by FACS. The ratios of b12 and b6 antibody
bindingMFIs are plotted as a function of the antibody concentration. In the context of SOS, both the V570D and I559Pmutations show a lower b12/b6 ratio than
the wt without SOS. (b) Wt Env with the SOS disulfide was only marginally more native-like than disulfide-stabilized Env with 6-HBDmutations. The binding
studies were done as described for panel a. Introduction of the SOS disulfide bond between residues A501C and T605C thus results in substantially decreased
discrimination between b12 and b6 antibodies. (c) Cleavage of disulfide-stabilized Envs analyzed by Western blotting. Equal volumes of total cell lysates from
Env-transfected cells were transferred to nitrocellulose membranes and probed with rabbit anti-gp120 polyclonal sera. gp160H is a higher-molecular-weight
hyperglycosylated species described in previous studies (16). gp160-SOSIP and gp160-SOS-V570D are both largely cleaved but are expressed at lower levels than
wt gp160 or SOS-gp160. Coexpression of furin marginally increased the extent of cleavage for these mutants but had less effect on cleavage of SOS-gp160.
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ing in JRFL Env resulted in structural reorganization with en-
hanced exposure of gp41 epitopes, which are occluded in native
Env. The cysteine mutation introduced in gp41 is proximal to the
native disulfide in gp41.We cannot exclude the possibility that the
extra cysteine could form a nonphysiological disulfide bond with
cysteine present in gp41 in the cell surface expression system used
here.
PG9 and PG16 are quaternary, epitope-specific, broadly
neutralizing antibodies. These antibodies recognize variable
loop region epitopes on gp120 in the context of the trimer (17,
51). Since wt JRFL gp160 does not bind to PG9 and PG16, we
introduced the E168K mutation to detect PG9 and PG16 bind-
ing (17). The E168K mutation was introduced into wt JRFL
gp160, JRFL gp160-V570D, SOSIP-gp160, and SOS-gp160-
V570D backgrounds for PG9 and PG16 antibody binding stud-
ies. Binding of PG9 and PG16 antibodies was significantly less
to SOSIP-gp160-E168K than to wt JRFL gp160-E168K, but the
coexpression of furin slightly improved binding to PG9 and
PG16 (Fig. 8a). SOSIP-gp160-E168K and SOSgp160-V570D
mutants bound5-fold and2-fold more weakly to PG9 and
PG16 on the cell surface than wt gp160-E168K (Fig. 8a). Re-
placing the cleavage site (REKR) with R6 improved the binding
of PG9 and PG16 antibodies. The gp160-E168K and gp160-
V570D-E168K mutants exhibited similar binding to PG9 and
PG16 (Fig. 8b).
DISCUSSION
In this study, we have characterized postfusion six-helix bundle-
disrupting mutations in the context of native Env trimers on the
cell surface. Native trimeric HIV-1 Env exists in a metastable con-
formation that is prone to form the highly stable postfusion six-
helix bundle conformation (4, 40). Mutations that interrupt
coiled-coil packing will destabilize the pre-hairpin intermediate
state and/or postfusion six-helix bundle formation and allow the
Env trimer to lock into the native conformation, where nonneu-
tralizing epitopes are expected to be occluded and neutralizing
epitopes are exposed efficiently. After CD4 receptor binding, Env
attains a more open quaternary-state conformation (52), and it
exposes immunodominant epitopes that are occluded on native
trimeric Env. In our previous work, we have screened various
mutations in NHR and CHR repeat regions (I559P, V570D,
I573D, and S649D) that disrupt six-helix bundle formation on the
yeast surface (31). We introduced these mutations into Env trim-
ers and expressed them on the mammalian cell surface to charac-
terize the mutations in the context of the native Env trimer. Bind-
ing studies with various gp120- and gp41-specific antibodies
showed that the six-helix bundle-destabilizing mutations (partic-
ularly V570D and I573D) did not perturb the native trimer con-
formation.
It was previously shown that the I559P mutation, in combina-
tion with the A501C and T605C mutations, stabilizes a trimeric,
FIG 7 Introduction of a disulfide bond between JRFL gp120 and gp41 results in increased exposure of the 2F5 and 4E10 epitopes. Env-expressing cells were
probed with the gp41-directed antibodies 2F5 and 4E10. MFIs were normalized for cell surface expression based on 2G12 antibody binding. The native
conformation of gp41 was perturbed in Env disulfide mutants, and coexpression of furin enabled the Env disulfide mutants to form a more native-like gp41
MPER epitope. Two independent transfection experiments were performed with similar results.
Stabilization of HIV-1 Native Env Trimer
September 2014 Volume 88 Number 17 jvi.asm.org 9599
 o
n
 August 28, 2017 by guest
http://jvi.asm.org/
D
ow
nloaded from
 
native-like conformation of Env (28, 39). Residue 559 occurs at
the “a” position of the NHR, and mutations at this position dis-
rupt or destabilize the NHR homotrimer present in the pre-hair-
pin intermediate and the postfusion 6-HB. The conformation of
the entire NHR region in native Env is not definitively known,
though a substantial part of it is helical and homotrimeric (19–
21). If residue 559 remains at the “a” position of the NHR ho-
motrimer in native Env, then it is possible that the I559Pmutation
may distort or destabilize the native Env structure, in addition to
its destabilizing effect on the 6-HB. Even if this region is not helical
in native Env, introduction of proline could perturb the structure,
given its constrained main chain dihedral angle 	 value of ap-
proximately65° and lack of an amide hydrogen (53). Since the
NHR-CHR interface is not formed in native Env (19–21), it is
important to explore the effects of mutations in this interface re-
gion on the stability of native Env. The present study shows that
I559P appears to perturb the native conformation of JRFL Env
more than V570D, though both destabilize the postfusion confor-
mation. Shed gp120 experiments suggest that six-helix bundle-
destabilizingmutations were able to lock Env in a native-like con-
formation while destabilizing the postfusion six-helix bundle.
Mutations in both the NHR and CHR regions of gp41 did not
FIG 8 SOSmutations decrease binding to gp120 trimer-specific antibodies PG9 and PG16, but binding was increased in the presence of the R6 cleavage site and
with furin coexpression. (a) Cells expressing disulfide Envmutants were stained with quaternary specific antibodies PG9 and PG16. Cell surface expression levels
were detected by 2G12 antibody binding. (b) Cells expressing wt gp160 and gp160-V570D without the SOSmutation were stained with PG9 and PG16. The two
envelopes showed identical binding. The MFIs were normalized for cell surface expression based on 2G12 antibody binding. Two independent transfection
experiments yielded similar results.
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affect the ability of gp120 subunits to bind neutralizing and non-
neutralizing antibodies, and additionally, they prevented sCD4-
induced gp120 shedding from the cell surface by shifting the equi-
librium toward the native conformation. The results suggest that
wild-type cleaved Env in the native trimer, once bound to CD4, is
able to transiently access conformations in which gp41 can form a
six-helix bundle or,minimally, conformations inwhich regions of
NHR and CHR interact as they do in the 6-HB.
Stabilizing Env in its native conformation is an important
problem in HIV-1 vaccine design. The labile nature of native Env
coupled with the high stability of coiled coils formed by NHR and
CHR of gp41 (4) means that native Env exists in a metastable
conformation. Structural changes in gp41 regions are linked with
conformational changes in gp120. The six-helix bundle-destabi-
lizing mutations screened in this study did not alter the native
conformation of gp120 trimer on Env (Fig. 2).We show that post-
fusion 6-HBD mutations help retain gp120 on the cell surface, in
part by preventing the sCD4-induced gp120 shedding process that
occurs prior to fusion (Fig. 4 and 5). 6-HBD mutations did not
alter the quaternary conformation of Env, which was probed by
PG9 and PG16 antibodies. The quaternary conformational
epitopes at the apex of the gp120 trimer (V1/V2 regions) are stable
due to the existence of gp41 in a native-like conformation. The
6-HBD mutations tested here diminished misfolding of Env and
assisted the display of native-like Env on the cell surface. In an
alternative approach, Crooks et al. (54) described enzymatic strat-
egies to remove nonnative forms of Env (junk Env) from virus-
like particles. The current 6-HBD mutations provide a genetic
strategy to minimize misfolding of Env on the cell surface.
Among the 6-HBD mutations characterized in this study, the
I559P and I573D mutations are at the hydrophobic core of the
postfusion NHR trimer and the V570D and S649Dmutations are
at the corresponding NHR-CHR interface. The I559P mutation
prevented gp120 shedding but partially exposed nonneutralizing
epitopes, as well. This suggests that in the context of the JRFL
sequence, the I559Pmutationmight have caused subtle changes in
the native gp41 conformation that alter cleavage efficiency and
gp120 conformation in Env trimers. In contrast, V570D and
I573D mutations did not appear to perturb the native trimer in-
tegrity as assessed by antibody binding to CD4bs (b12 and b6),
CD4-induced epitopes (17b), V1/V2 quaternary epitopes (PG9
and PG16), and gp41 cluster I (D49) and MPER (2F5 and 4E10)
epitopes. The V570D, I573D, and I559P mutations all abolished
gp120 shedding in the presence of sCD4 and have slightly in-
creased binding of 2G12 neutralizing antibody in the presence of
sCD4. Although the S649D mutation disrupted six-helix bundle
formation on the yeast surface and maintained trimer integrity
(31), it failed to abolish gp120 shedding from the Env trimer in the
presence of sCD4. gp160-SEKS is a cleavage-defective Env in
which the cleavage site between gp120 and gp41 is mutated to
covalently link gp120 and gp41. Immunization studies with cleav-
age-defective Env have failed to elicit neutralizing antibodies.
Cleavage-defective Env bound equally well to both neutralizing
(b12) and nonneutralizing (b6) antibodies (16). The deviation
from the native Env conformation and exposure of nonneutraliz-
ing epitopes are further confirmed by its increased binding to
anti-gp120 polyclonal sera and other nonneutralizing monoclo-
nal antibodies. Due to the presence of covalent linkage between
gp120 and gp41 at the cleavage site, cleavage-defective Env pre-
vented sCD4-induced gp120 shedding but exposed immunodom-
inant regions (the cluster I region) of gp41 in the presence of
sCD4. The MPER region, which is partially buried in the native
Env conformation, was exposed in cleavage-defective Env (32).
Cleavage-defective Env failed to stabilize Env in the native confor-
mation and instead presented nonneutralizing epitopes, which
likely dominate the immune response.
In previous studies, gp120 and gp41 interactions were stabi-
lized by introducing a disulfide bond between the gp120 and gp41
subunits, along with the I559P mutation. gp140 constructs with
these three mutations are referred to as SOSIP-gp140 (27, 39).
SOSIP-gp140was cleaved efficiently following cotransfectionwith
furin and formed a significant amount of trimeric species. Immu-
nization studies showed that soluble, disulfide-stabilized SOSIP-
gp140 immunogens are better at eliciting neutralizing antibodies
than monomeric gp120 immunogens (30). Although they have
failed to elicit neutralizing antibodies that can neutralize diverse
HIV-1 isolates, they are among the better trimeric Env immuno-
gens designed so far. Cryo-EM structural analysis of SOSIP-gp140
trimers indicated that their topology is similar to that of native
HIV-1 Env trimers (46). In native Env trimers, three gp120 mol-
ecules associate at the apex of the envelope to form quaternary
epitopes that are targets for cross protective neutralization (19, 20,
52). PG9 and PG16 antibodies are quaternary specific antibodies,
and they recognize theV1/V2 regions of gp120 in the native trimer
conformation. Soluble KNH1144 SOSIP-gp140 trimers were
poorly recognized by PG9 and PG16 antibodies in ELISA studies
in earlier reports (17), though significant binding was recently
seen with BG505 SOSIP-gp140 (28). In the present study, we have
shown that JRFL SOSIP Env trimers on the cell surface deviated
from the native Env conformation and bound weakly to the qua-
ternary specific PG9 and PG16 antibodies. Introduction of the
V570D mutation instead of the I559P mutation in SOSIP-gp160
increased binding to PG9 and PG16. On the cell surface, disulfide
bond-stabilized trimers without the I559Pmutation (SOS-gp160)
are bettermimics of native conformation than SOSIP-Env trimers
(SOSIP-gp160) (Fig. 6), but soluble SOS-gp140 immunogens are
predominantly monomeric when expressed and purified in solu-
ble form (26, 39). The cryo-EM structures of the SOS-gp160
CT
trimer exhibited a tripod conformation (55), although the native
Env trimer does not exist in a tripod conformation (40, 52). The
cryo-EM structures of soluble KNH1144 and JRFL SOSIP-gp140
trimers were also solved (46, 56). In these structures, the densities
at the gp120 trimer association interface where quaternary neu-
tralizing epitopes exist are weak compared to those of native
HIV-1 Env trimers. This might be due to the lack of proper gp120
trimer association at the apex of the Env trimer. Our studies with
quaternary specific PG9 and PG16 antibodies are consistent with
the weak gp120 trimer association densities in these disulfide
trimers (Fig. 8). However, recent studies of SOSIP gp140 deriva-
tives from the BG505 isolate with MPER deleted have indicated
that these derivatives are quite similar to native Env in terms of
antibody binding profiles (28). It would therefore be interesting to
compare the V570D, I573D, and I559P mutants in this back-
ground. The difference in stability of Env on the cell surface and in
soluble form makes it difficult to directly compare 6-HBD muta-
tions on the cell surface and in soluble constructs. TheTMdomain
in cell surface Env maymake an additional contribution to stabil-
ity relative to soluble constructs, which lack TM and in some cases
the MPER region. Since, BG505 trimers with TM and MPER de-
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leted are stable, the 6-HBD mutations described here can also be
incorporated into such soluble constructs.
An ideal HIV-1 trimeric Env immunogen should expose neu-
tralizing epitopes and occlude immunodominant nonneutraliz-
ing epitopes. Stabilization of Env in its native conformation will
assist in the design of improved vaccine candidates that may elicit
cross protective neutralizing antibodies. The mutations reported
here (V570D and I573D) destabilize the postfusion conformation
while minimally perturbing the native conformation, indicating
these residues are surface proximal in native Env. Residue 573 is at
the a position of theNHR.However, the present data indicate that
this region, which is located close to the C terminus of the NHR in
the 6-HB, is unlikely to be part of a homotrimeric coiled coil in
native Env, since burial of aspartic acid at the interior of the ho-
motrimer is expected to be highly destabilizing (37, 57). It was
recently reported (58) that DNA priming with JRFL Env and tat
followed by a gp140 protein boost elicited encouraging neutral-
ization in nonhuman primates. The V570D and I573Dmutations
described above can also be used to stabilize native Env in a DNA
vaccine format.
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